Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Pencil Beam Proton Therapy Revolutionize Cancer Care?

Executive Summary

In the billion dollar market for radiotherapy products, pencil beam proton therapy could potentially revolutionize cancer care but the technology is very expensive, and it remains to be seen how many medical institutions in the US and worldwide will be interested in adopting the large systems, which require years to construct. Scripps Proton Therapy Center medical director Carl Rossi, MD, speaks about the benefits of proton therapy compared with other types of radiation therapy.

You may also be interested in...



Global Radiation Therapy Systems Market Expected to Reach $5.6B by 2020

Although immunotherapy and other cutting-edge technologies have dominated the spotlight in cancer treatment over the last several years, the use of radiation therapy is rapidly increasing as physicians look to this non-invasive, cost-effective treatment to address a broad and growing number of cancers. Valued at nearly $4.3 billion in 2015, the global radiation therapy market is growing at a CAGR of 5.5%, and is projected to reach $5.6 billion by 2020, according to a recent report from Medtech Insight.

Reducing Radiation Exposure

The use of cancer radiation therapy and interventional fluoroscopy is expanding rapidly, and medtech start-ups are pioneering innovative technologies to capitalize on the industry-wide movement to reduce radiation exposure and improve outcomes. Profiles of ControlRad Systems, Nanovi, and SoniTrack Systems.

Pink Sheet Podcast: Drug Pricing Campaign Future, Lilly’s Instagram Issue, Drug Withdrawal … Or Not

Pink Sheet reporters and editors discuss whether a new report on generic drug prices will affect efforts to green-light government price negotiations, Eli Lilly’s untitled letter for promotion on Instagram, and Oncopeptides deciding to withdraw its accelerated approval withdrawal.

Topics

Related Companies

UsernamePublicRestriction

Register

MT035771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel